Pratt C B, Champion J E, Fleming I D, Rao B, Kumar A P, Evans W E, Green A A, George S
Department of Hematology/Oncology, St. Jude Children's Research Hospital, Memphis, TN 38101-0318.
Cancer. 1990 Feb 1;65(3):439-45. doi: 10.1002/1097-0142(19900201)65:3<439::aid-cncr2820650311>3.0.co;2-w.
Seventy-six patients with classic high-grade osteosarcoma of an extremity received adjuvant chemotherapy by two protocols, initiated in 1972 and 1977, respectively, after appropriate amputations. Chemotherapy consisted of high-dose methotrexate, doxorubicin, and cyclophosphamide. Dose intensity of high-dose methotrexate and doxorubicin was greater for the patients treated with the protocol initiated in 1977. The proportion of long-term disease-free survivors on the two protocols are 46% and 56%. A better outcome (P = 0.042) was seen for the latter group, which received more intensive chemotherapy. Overall, metastases developed in 35 patients; in 19 who were receiving chemotherapy and in 16 after chemotherapy. The outcome for these two protocols, compared with two control groups that were given no chemotherapy or ineffective chemotherapy (biweekly vincristine and cyclophosphamide), confirms the results of controlled studies that showed an advantage of adjuvant chemotherapy after amputation for osteosarcoma.
76例患有肢体经典型高级别骨肉瘤的患者分别于1972年和1977年在进行适当截肢术后，按照两种方案接受辅助化疗。化疗方案包括大剂量甲氨蝶呤、阿霉素和环磷酰胺。1977年开始采用该方案治疗的患者，其大剂量甲氨蝶呤和阿霉素的剂量强度更高。两种方案的长期无病生存率分别为46%和56%。接受更强化化疗的后一组患者预后更好（P = 0.042）。总体而言，35例患者发生了转移；其中19例在接受化疗期间发生转移，16例在化疗后发生转移。与未接受化疗或接受无效化疗（每两周一次长春新碱和环磷酰胺）的两个对照组相比，这两种方案的治疗结果证实了对照研究的结果，即截肢术后辅助化疗对骨肉瘤具有优势。
